Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma

Trial Profile

Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Pazopanib (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Haemangiosarcoma; Liposarcoma; Malignant melanoma; Mesothelioma; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Sarcoma; Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2017.
    • 19 Apr 2017 Status changed from completed to active, no longer recruiting.
    • 07 Jun 2016 Results from Phase II part of this trials (n=33) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top